Nuo Therapeutics, Inc. (AURX) shareholders
AURXOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$1.26−0.04 (-3.08%)
Close on Oct 19, 2026Market cap $61.08MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 48M shares
Institutional holders
1
0 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
2 buys · 1 sales
Net sold $290.45K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Pittman Scott M. | 5,627,500 | 11.60% | 13D (active) amendment | May 29, 2026 |
| Jacobs Paul Anthony | 3,183,500 | 6.60% | 13G (passive) amendment | Jan 23, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AURX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ancora Advisors, LLC | 4,700 | 0.01% | $4.28K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2026 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2025 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2025 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David Emerson Jorden | CEO/CFO, Director | 2,070,190 | 4.27% | Aug 31, 2026 |
| Peter Clausen | CSO/COO | 773,528 | 1.60% | Jul 2, 2026 |
| Scott M. Pittman | Director, 10% owner | 5,440,000 | 11.23% | Oct 6, 2026 |
| Paul Mintz | Director | 108,294 | 0.22% | Jul 2, 2026 |
| C. Eric Winzer | Director | 212,654 | 0.44% | Jul 2, 2026 |
| Charles E. Sheedy | 10% owner | 11,574,198 | 23.90% | Aug 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Emerson Jorden CEO/CFO, Director | Aug 28, 2026 | Buy | +7,984 | $1.09 | $8.70K | 2,070,000 |
| David Emerson Jorden CEO/CFO, Director | Aug 28, 2026 | Award | +7,984 | $1.09 | $8.70K | 2,070,000 |
| David Emerson Jorden CEO/CFO, Director | Aug 27, 2026 | Buy | +789 | $1.07 | $844 | 2,062,016 |
| David Emerson Jorden CEO/CFO, Director | Aug 27, 2026 | Award | +789 | $1.07 | $844 | 2,062,016 |
| David Emerson Jorden CEO/CFO, Director | Jun 30, 2026 | Option exercise | +162,500 | $1.00 | $162.50K | 2,222,119 |
| David Emerson Jorden CEO/CFO, Director | Jun 30, 2026 | Tax withholding | −160,892 | $1.01 | $162.50K | 2,061,227 |
| C. Eric Winzer Director | Jun 30, 2026 | Option exercise | +40,000 | $1.00 | $40.00K | 212,654 |
| C. Eric Winzer Director | Jun 30, 2026 | Tax withholding | −39,604 | $1.01 | $40.00K | 173,050 |
| Scott M. Pittman Director, 10% owner | Jun 30, 2026 | Option exercise | +40,000 | $1.00 | $40.00K | 5,440,000 |
| Scott M. Pittman Director, 10% owner | Jun 30, 2026 | Tax withholding | −39,604 | $1.01 | $40.00K | 5,400,396 |
| David Emerson Jorden CEO/CFO, Director | Jun 5, 2026 | Award | +13,245 | $1.10 | $14.57K | 2,085,000 |
| David Emerson Jorden CEO/CFO, Director | Jan 1, 2026 | Tax withholding | −25,381 | $1.97 | $50.00K | 2,046,374 |
| David Emerson Jorden CEO/CFO, Director | Jan 1, 2026 | Option exercise | +125,000 | $0.40 | $50.00K | 2,071,755 |
| C. Eric Winzer Director | Dec 17, 2025 | Option exercise | +68,750 | $0.40 | $27.50K | 186,404 |
| C. Eric Winzer Director | Dec 17, 2025 | Tax withholding | −13,750 | $2.00 | $27.50K | 172,654 |
| Paul Mintz Director | Dec 9, 2025 | Tax withholding | −9,091 | $2.20 | $20.00K | 108,294 |
| Paul Mintz Director | Dec 9, 2025 | Option exercise | +50,000 | $0.40 | $20.00K | 117,385 |
| Paul Mintz Director | Dec 9, 2025 | Option exercise | +50,000 | $0.40 | $20.00K | 117,385 |
| Paul Mintz Director | Dec 9, 2025 | Tax withholding | −9,091 | $2.20 | $20.00K | 108,294 |
| David Emerson Jorden CEO/CFO, Director | Nov 28, 2025 | Sale | −200,000 | $1.50 | $300.00K | 1,946,755 |
| Paul Mintz Director | Aug 1, 2025 | Option exercise | +87,500 | $0.40 | $35.00K | 87,500 |
| Paul Mintz Director | Aug 1, 2025 | Tax withholding | −20,115 | $1.74 | $35.00K | 67,385 |
| C. Eric Winzer Director | Aug 1, 2025 | Option exercise | +120,313 | $0.40 | $48.13K | 145,313 |
| C. Eric Winzer Director | Aug 1, 2025 | Tax withholding | −27,659 | $1.74 | $48.13K | 117,654 |
| David Emerson Jorden CEO/CFO, Director | Aug 1, 2025 | Option exercise | +92,710 | $0.40 | $37.08K | 2,168,068 |
| David Emerson Jorden CEO/CFO, Director | Aug 1, 2025 | Option exercise | +100,000 | $0.40 | $40.00K | 2,075,358 |
| David Emerson Jorden CEO/CFO, Director | Aug 1, 2025 | Tax withholding | −21,313 | $1.74 | $37.08K | 2,146,755 |
| C. Eric Winzer Director | Aug 1, 2025 | Tax withholding | −27,659 | $1.74 | $48.13K | 117,654 |
| C. Eric Winzer Director | Aug 1, 2025 | Option exercise | +120,313 | $0.40 | $48.13K | 145,313 |
| Peter Clausen CSO/COO | Jul 31, 2025 | Option exercise | +183,853 | $0.40 | $73.54K | 770,054 |
| Charles E. Sheedy 10% owner | Jul 30, 2025 | Buy | +133,333 | $1.50 | $200.00K | 11,570,833 |
| Scott M. Pittman Director, 10% owner | Jul 30, 2025 | Award | +3,946 | $1.50 | $5.92K | 5,400,000 |
| Scott M. Pittman Director, 10% owner | Nov 15, 2024 | Option exercise | +62,500 | $0.40 | $25.00K | 5,362,720 |
| Scott M. Pittman Director, 10% owner | Nov 15, 2024 | Option exercise | +33,334 | $0.50 | $16.67K | 5,396,054 |
| Scott M. Pittman Director, 10% owner | Nov 15, 2024 | Option exercise | +121,875 | $0.40 | $48.75K | 5,300,220 |
| Charles E. Sheedy 10% owner | Sep 18, 2024 | Buy | +125,000 | $0.75 | $93.75K | 11,437,500 |
| Charles E. Sheedy 10% owner | May 20, 2024 | Buy | +100,000 | $0.75 | $75.00K | 11,312,500 |
| Scott M. Pittman Director, 10% owner | May 20, 2024 | Award | +135,000 | $0.75 | $101.25K | 5,178,345 |
| Peter Clausen CSO/COO | May 20, 2024 | Award | +15,000 | $0.75 | $11.25K | 586,201 |
| Peter Clausen CSO/COO | Dec 19, 2023 | Award | +20,000 | $0.50 | $10.00K | 571,201 |
| Charles E. Sheedy 10% owner | Dec 19, 2023 | Buy | +150,000 | $0.50 | $75.00K | 11,212,500 |
| Scott M. Pittman Director, 10% owner | Dec 19, 2023 | Award | +600,000 | $0.50 | $300.00K | 5,043,345 |
| Charles E. Sheedy 10% owner | Aug 1, 2023 | Buy | +62,500 | $2.00 | $125.00K | 11,062,500 |
| Peter Clausen CSO/COO | Aug 1, 2023 | Award | +25,000 | $2.00 | $50.00K | 551,201 |
| Scott M. Pittman Director, 10% owner | Aug 1, 2023 | Award | +100,000 | $2.00 | $200.00K | 4,443,345 |
| David Emerson Jorden CEO/CFO, Director | Nov 9, 2022 | Sale | −20,000 | $1.50 | $30.00K | 2,010,858 |
| David Emerson Jorden CEO/CFO, Director | Nov 9, 2022 | Sale | −30,000 | $1.50 | $45.00K | 2,077,858 |
| David Emerson Jorden CEO/CFO, Director | Nov 9, 2022 | Sale | −27,000 | $1.50 | $40.50K | 2,050,858 |
| David Emerson Jorden CEO/CFO, Director | Nov 9, 2022 | Sale | −13,500 | $1.50 | $20.25K | 1,997,358 |
| David Emerson Jorden CEO/CFO, Director | Nov 9, 2022 | Sale | −30,000 | $1.50 | $45.00K | 2,107,858 |
| David Emerson Jorden CEO/CFO, Director | Nov 9, 2022 | Sale | −7,000 | $1.50 | $10.50K | 1,980,358 |
| David Emerson Jorden CEO/CFO, Director | Nov 9, 2022 | Sale | −5,000 | $1.50 | $7.50K | 1,975,358 |
| David Emerson Jorden CEO/CFO, Director | Nov 9, 2022 | Sale | −10,000 | $1.50 | $15.00K | 1,987,358 |
| David Emerson Jorden CEO/CFO, Director | Nov 9, 2022 | Sale | −20,000 | $1.50 | $30.00K | 2,030,858 |
| Scott M. Pittman Director, 10% owner | Apr 29, 2022 | Award | +100,000 | $1.00 | $100.00K | 4,343,345 |
| Peter Clausen CSO/COO | Apr 29, 2022 | Award | +25,000 | $1.00 | $25.00K | 526,201 |
| Charles E. Sheedy 10% owner | Apr 29, 2022 | Buy | +804,868 | $1.00 | $804.87K | 11,000,000 |
| David Emerson Jorden CEO/CFO, Director | Apr 29, 2022 | Award | +10,532 | $1.00 | $10.53K | 2,137,858 |
| Charles E. Sheedy 10% owner | Dec 30, 2021 | Option exercise | +1,431,615 | $0.20 | $286.32K | 10,195,132 |
| Scott M. Pittman Director, 10% owner | Dec 30, 2021 | Option exercise | +900,000 | $0.20 | $180.00K | 4,243,345 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+4872.4%
From 0M shares
Short volume, 0 days
–
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nuo Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?